

Challenging Cases in Colorectal Cancer

Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty

The first of 6 integrated symposia in an oncology curriculum

CNE INFORMATION

TARGET AUDIENCE

This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of colorectal cancer (CRC).

OVERVIEW OF ACTIVITY

Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States, accounting for approximately 9% of all cancer deaths. In the year 2013 it is estimated that 102,480 new cases of colon cancer and 40,340 new cases of rectal cancer will be documented in the US, representing a continued decline over the past 2 decades thought to be related to improvements in detection and treatment. Current therapeutic management of CRC is dependent on tumor stage at the time of initial diagnosis, status of surgical margins, patient performance status, age, prior treatment exposure and sites of metastasis for those with disease recurrence or de novo advanced cancer. Although these variables are helpful in guiding selection of treatment, the introduction of novel biomarkers, multigene signatures and molecular-targeted systemic agents has significantly refined the clinical algorithm such that individualized therapeutic approaches have become the standard. This paradigm shift presents a challenge to practicing oncologists and other members of the treatment team who must grapple with the presentation of ambiguous data sets and their immediate impact on management decisions. These factors support the pivotal position of nurses as caregivers, communicators and educators in the comprehensive care of patients with CRC.

These video proceedings from the first part of a 6-part integrated CNE curriculum originally held at the 2013 ONS Annual Congress feature discussions with leading gastrointestinal cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario. By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation

of state-of-the-art clinical management strategies to facilitate optimal care of patients with CRC.

LEARNING OBJECTIVES

- Apply existing and emerging research data to the therapeutic and supportive care of patients with metastatic CRC (mCRC).
- Use case-based learning to gain familiarity with new therapeutic strategies for mCRC in order to facilitate improved counseling for patients.
- Develop an evidence-based algorithm for the prevention and amelioration of side effects associated with chemotherapeutic and biologic agents used in the management of mCRC.
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with mCRC to optimize clinical and quality-of-life outcomes.
- Recall ongoing trials of investigational approaches and agents in mCRC, and consent and refer patients for study participation.

ACCREDITATION STATEMENT

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

CREDIT DESIGNATION STATEMENT

This educational activity for 2.0 contact hours is provided by Research To Practice during the period of July 2013 through July 2014.

HOW TO USE THIS CNE ACTIVITY

This CNE activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ONSCRC2013/Video/CNE.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Charles S Fuchs, MD, MPH

Director, Center for Gastrointestinal Cancer
Dana-Farber/Harvard Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Pfizer Inc, Sanofi.

Axel Grothey, MD

Professor of Oncology
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Contracted Research: Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech BioOncology, Lilly USA LLC.

Jessica Mitchell, RN, CNP, MPH

Certified Nurse Practitioner
GI Medical Oncology
Mayo Clinic
Rochester, Minnesota

Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals.

Tammy Triglianos, RN, MS, APRN, BC, AOCNP

GI Oncology Nurse Practitioner
Lineberger Comprehensive Cancer Center at
The University of North Carolina
Chapel Hill, North Carolina

No real or apparent conflicts of interest to report.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals and Genentech BioOncology.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center

Last review date: July 2013

Expiration date: July 2014

SELECT PUBLICATIONS

- Abdalla EK et al. **Improving resectability of hepatic colorectal metastases: Expert consensus statement.** *Ann Surg Oncol* 2006;13(10):1271-80.
- Abrams TA et al. **Patterns of chemotherapy (CT) use in a US-wide population-based cohort of patients (pts) with metastatic colorectal cancer (mCRC).** *Proc ASCO* 2012;Abstract 3537.
- Arnold D et al. **Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).** *Proc ASCO* 2012;Abstract CRA3503.
- Donadon M et al. **New paradigm in the management of liver-only metastases from colorectal cancer.** *Gastrointest Cancer Res* 2007;1(1):20-7.
- Fernandez FG et al. **Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET).** *Ann Surg* 2004;240(3):438-47.
- Grothey A et al. **Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial.** *Lancet* 2013;381(9863):303-12.
- Grothey A et al. **Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE).** *J Clin Oncol* 2008;26(33):5326-34.
- Lacouture ME et al. **Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer.** *J Clin Oncol* 2010;28(8):1351-7.
- McCahill LE et al. **Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10.** *J Clin Oncol* 2012;30(26):3223-8.
- McLoughlin JM et al. **Resection of colorectal liver metastases: Current perspectives.** *Cancer Control* 2006;13(1):32-41.
- Meyerhardt JA et al. **Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803.** *J Clin Oncol* 2006;24(22):3535-41.
- Nordlinger B et al. **EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.** *Proc ASCO* 2012;Abstract 3508.
- Nordlinger B et al. **Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial.** *Lancet* 2008;371(9617):1007-16.
- Pawlik TM et al. **Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.** *Ann Surg* 2005;241(5):715-24.
- Poultides GA et al. **Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment.** *J Clin Oncol* 2009;27(20):3379-84.
- Van Cutsem E et al. **Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.** *J Clin Oncol* 2012;30(28):3499-506.
- Zhu Y et al. **Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal metastases.** *J Gastrointest Oncol* 2013;4(1):62-71.